Notizie AIOM – anno XV n. 648

24 Ottobre 2017

FDA Grants Priority Review to Frontline Cabozantinib in RCC

October 16, 2017 - The FDA has granted a priority review to a supplemental new drug application (sNDA) for cabozantinib for previously untreated patients with advanced renal cell carcinoma (RCC), according to Exelixis, the developer of the multikinase inhibitor. The sNDA ...
Leggi tutto

24 Ottobre 2017

NICE Rejects Treatments for Bladder and Thyroid Cancer

October 20, 2017 - The UK’s National Institute for Health and Care Excellence (NICE) has issued guidelines recommending against nivolumab for routine use in patients with previously-treated advanced urothelial carcinoma. The agency also recommended against lenvatinib ...
Leggi tutto

24 Ottobre 2017

Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial

Patients with colorectal cancer (CRC) receiving oxaliplatin (OXA) develop acute and chronic painful oxaliplatin-induced peripheral neuropathy (OXAIPN). Acute and chronic OXA-related neuropathies have different pathophysiological bases, but both lead to a common phenomenon: ...
Leggi tutto

24 Ottobre 2017

18 ottobre 2017 – Nuova versione di EudraVigilance: cosa cambia per il sistema italiano di FV a partire dal 22 novembre

23 Ottobre 2017

20 ottobre 2017 – Monitoraggio della Spesa Farmaceutica Nazionale e Regionale (gennaio / giugno 2017)

20 Ottobre 2017

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma

October 18, 2017 - The U.S. Food and Drug Administration today approved axicabtagene ciloleucel, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of ...
Leggi tutto

20 Ottobre 2017

Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer

October 16, 2017 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the existing marketing authorization for abiraterone acetate to include use in combination with prednisone/prednisolone and androgen deprivation ...
Leggi tutto

20 Ottobre 2017

Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients

Primary cytoreduction, followed by chemotherapy, is a standard treatment of patients with epithelial ovarian cancer (EOC). However, the effectiveness of this treatment depend on various elements e.g. type of operation. It is accepted that optimal surgery correlates with ...
Leggi tutto

20 Ottobre 2017

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) compared the continuation of gefitinib plus chemotherapy with placebo plus chemotherapy in patients with epidermal growth factor receptor (EGFR) mutation–positive advanced non–small-cell ...
Leggi tutto

20 Ottobre 2017

Norman E. Sharpless, MD, Sworn in as Director of the National Cancer Institute

October 18, 2017 - Norman E. “Ned” Sharpless, MD, took the oath of office late Tuesday, October 17, 2017, to become the 15th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). He succeeds Harold E. Varmus, MD, who ...
Leggi tutto

LAVORIAMO CON

News

MEDICINA DI LABORATORIO, OLTRE IL 70% DELLE DECISIONI CLINICHE DIPENDE DALLE ANALISI. PRESENTATO IL PRIMO STUDIO NAZIONALE SULL’APPLICAZIONE DEL NUOVO NOMENCLATORE TARIFFARIO

TUMORI: “CNAO È CENTRO DI RIFERIMENTO MONDIALE NELL’ADROTERAPIA. A OGGI TRATTATI PIÙ DI 6.200 PAZIENTI”

MALATTIE AUTOIMMUNI: AL GIFFONI FILM FESTIVAL ARRIVA “PIÙ FORTE IO”. CON TENACIA E NUOVE TERAPIE POSSIBILE SUPERARE LE PATOLOGIE CRONICHE

L’OCULISTA: ANCHE IN ESTATE POSSIBILE FARSI OPERARE DI GLAUCOMA. PER PROTEGGERE GLI OCCHI BASTANO MASCHERINE, CAPPELLINI E OCCHIALI

MEDICINA DI LABORATORIO, I CLINICI ITALIANI RICONOSCIUTI TRA LE ECCELLENZE INTERNAZIONALI. “IL NOSTRO PAESE TRA I PROTAGONISTI DELL’EVOLUZIONE DELLA DIAGNOSTICA NEL MONDO”

TUMORE DELL’OVAIO, 1 DONNA SU 3 ASPETTA PIÙ DI UN ANNO PER LA DIAGNOSI. “NECESSARIO AUMENTARE L’ACCESSO AI CENTRI AD ALTO VOLUME, AL SUPPORTO PSICONCOLOGICO E ALL’INNOVAZIONE TERAPEUTICA”

TUMORE DEL SENO, IN ITALIA 950MILA DONNE VIVONO CON UNA DIAGNOSI. ROPI: ‘RACCOMANDATI ALMENO 150 MINUTI D’ATTIVITA’ FISICA ALLA SETTIMANA’

Notizie AIOM – anno XV n. 648

FDA Grants Priority Review to Frontline Cabozantinib in RCC

NICE Rejects Treatments for Bladder and Thyroid Cancer

Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial

18 ottobre 2017 – Nuova versione di EudraVigilance: cosa cambia per il sistema italiano di FV a partire dal 22 novembre

20 ottobre 2017 – Monitoraggio della Spesa Farmaceutica Nazionale e Regionale (gennaio / giugno 2017)

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma

Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer

Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Norman E. Sharpless, MD, Sworn in as Director of the National Cancer Institute